Cytokines as therapeutic targets in SLE. (Q37741799)

22 August 2017

1 reference

title

Cytokines as therapeutic targets in SLE. (English)

1 reference

22 August 2017

Lars Rönnblom

1 reference

22 August 2017

Keith B Elkon

series ordinal

1 reference

22 August 2017

language of work or name

English

0 references

publication date

4 May 2010

1 reference

Nature Reviews Rheumatology

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

339-347

1 reference

Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Review of recent genome-wide association scans in lupus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Recent insights into the genetic basis of systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Genetics of rheumatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

BAFF and MyD88 signals promote a lupuslike disease independent of T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

31 March 2020

Cracking the BAFF code.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

TACI and BAFF-R mediate isotype switching in B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Novel evidence-based systemic lupus erythematosus responder index

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

The role of tumor necrosis factor-alpha in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

The pathophysiology of tumor necrosis factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Autoimmune Diseases Induced by TNF-Targeted Therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Serum interferon levels in patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Microarray analysis of gene expression in lupus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Type I interferons (alpha/beta) in immunity and autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Interleukin-6: discovery of a pleiotropic cytokine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Cytokine balance in kidney tissue from lupus nephritis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Interferon-γ: an overview of signals, mechanisms and functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Immunological and inflammatory functions of the interleukin-1 family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

IL-1RA in refractory systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Interleukin-10: new perspectives on an old cytokine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Th17 and natural Treg cell population dynamics in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

The biological functions of T helper 17 cell effector cytokines in inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

New insights into the regulation of T cells by gamma(c) family cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Novel targeted therapies for autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

A polymorphism within IL21R confers risk for systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.64

Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20440285

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20440285

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20440285

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2010.64

1 reference

22 August 2017

1 reference